167 Old Post Road, 2nd Floor
10 articles with Thetis Pharmaceuticals
Thetis Pharmaceuticals Receives Orphan Drug Designation from FDA for Resolvin E1 Therapy for Pancreatic Cancer
Thetis Pharmaceuticals (“Thetis”), a leading developer of Resolvin-based therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TP-317 for treatment of pancreatic cancer.
Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company developing Resolvin-based therapies, announced today the launch of a new program in cancer and the formation of a scientific advisory board (SAB) with several prominent cancer researchers and industry veterans.
Thetis Pharmaceuticals Announces Completion of Pre-IND Meeting with FDA for Development of its Resolvin E1 Candidate, TP-317, for Inflammatory Bowel Disease
Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it completed a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration for its lead candidate, TP-317, a Resolvin E1 oral, small molecule therapy being developed for inflammatory bowel disease (IBD).
Thetis Pharmaceuticals Receives Orphan Drug Designation for Resolvin E1 Program in Pediatric Ulcerative Colitis
Thetis’ drug candidate TP-317 is a first-in-class small molecule oral therapy in development for inflammatory bowel disease (IBD).
Thetis Pharmaceuticals Receives Funding from the Crohn's & Colitis Foundation to Support Investigational Mucosal Healing Therapy for Inflammatory Bowel Disease
Crohn's & Colitis Foundation's IBD Ventures award supports development of Thetis' novel first-in-class Resolvin oral therapy (TP-317) for treatment of ulcerative colitis and Crohn's disease
3/8/2019Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
Thetis Pharmaceuticals Awarded $2.3M Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease
Resolvin-based agent targets inflammation resolution and tissue regeneration without immunosuppression.
Thetis To Present At The World Orphan Drug Congress On TP-252, An Investigational Drug For Familial Adenomatous Polyposis